Clinical Pharmacokinetic and Pharmacodynamic Profile of Etoricoxib

@article{Takemoto2008ClinicalPA,
  title={Clinical Pharmacokinetic and Pharmacodynamic Profile of Etoricoxib},
  author={Jody K. Takemoto and Jonathan K. Reynolds and Connie M. Remsberg and Karina R. Vega-Villa and Neal M. Davies},
  journal={Clinical Pharmacokinetics},
  year={2008},
  volume={47},
  pages={703-720}
}
The NSAID etoricoxib is a selective inhibitor of cyclo-oxygenase 2 (COX-2), approved for treatment of patients with chronic arthropathies and musculoskeletal and dental pain. The rate of absorption of etoricoxib is moderate when given orally (the maximum plasma drug concentration occurs after ∼1 hour), and the extent of absorption is similar with oral and intravenous doses. Etoricoxib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 120 L… 
Detection and Pharmacokinetics of Etoricoxib in Thoroughbred Horses.
Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect.
TLDR
The pharmacokinetic profile demonstrated that there was an increase in diclofenac elimination and a lower exposure todicl ofenac with administration of DICCIC compared to dIClofanac.
Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model
TLDR
The data support the safe single-dose administration and in vivo efficacy of fluorocoxib A and suggest a high potential for successful translation to clinical use as an imaging agent for improved tumor detection in humans.
Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection
TLDR
There was no up-regulation of ACE2 mRNA/protein expression and activity in lung, heart and aorta tissue in ibuprofen-treated mice in comparison to untreated mice, and viral load was significantly reduced by both flurbiprofen and ib uprofen at high concentrations.
Pharmacokinetic characterization of fluorocoxib D, a cyclooxygenase-2-targeted optical imaging agent for detection of cancer
TLDR
The results suggest that fluorocoxib D is a safe optical imaging agent used for detection of COX-2-expressing cancers and their margins during image-guided minimally invasive biopsy and surgical procedures.
Adverse Effects of Etoricoxib, a Selectively Inhibiting Cyclo-Oxygenase-2 Anti-Inflammatory Drug, Assessed on Ants Used as a Model
TLDR
Etoricoxib appears to present less adverse effects than diclofenac and meloxicam, two traditional anti-inflammatory drugs, andMeloxicam appears not to change the locomotion and memorization abilities.
A Review on Various Analytical Methodologies for Etoricoxib
TLDR
This study focuses primarily on analytical and bioanalytical method development methodologies, as well as numerous methods established for the estimation of etoricoxib, whether in pharmaceutical dose form or in bulk.
An update on the pharmacogenomics of NSAID metabolism and the risk of gastrointestinal bleeding
TLDR
The relationship between CYP2C9 polymorphisms and the risk of developing NSAID-related gastrointestinal bleeding, as well as other adverse gastrointestinal events, is revised, and an allele-specific effect in the association is observed: CYP1C9*2 is a poor risk predictor, whereas CYP3C8*3 is a highly significant predictor of gastrointestinal adverse events and gastrointestinal bleeding.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 81 REFERENCES
Pharmacokinetics of Rofecoxib
TLDR
COX-2 inhibitors represent a major therapeutic advance in terms of gastrointestinal safety; however, long-term safety in other organ systems and with concomitant drug administration still remain to be proven.
Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib
Celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), is the first specific inhibitor of cyclo-oxygenase-2 (COX-2) approved to treat patients with rheumatism and osteoarthritis. Preliminary data
Effects of etoricoxib on the pharmacokinetics of phenytoin.
TLDR
It is suggested that etoricoxib alters the pharmacokinetics of phenytoin, which will warrant changes in pheny toin dose or frequency when etoricxib is co-administered with it.
The Effect of Etoricoxib on the Pharmacodynamics and Pharmacokinetics of Warfarin
TLDR
The effects of etoricoxib on pharmacodynamic and pharmacokinetic parameters of warfarin and the international normalized ratio of patients coadministered oral anticoagulants and etoricxib should be closely monitored, particularly during initiation of therapy.
Single‐ and Multiple‐Dose Pharmacokinetics of Etoricoxib, a Selective Inhibitor of Cyclooxygenase‐2, in Man
TLDR
Steady‐state pharmacokinetics of etoricoxib, achieved following 7 days of once‐daily dosing, were found to be reasonably predicted from single doses, and the drug was generally well tolerated.
Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers.
TLDR
In healthy male subjects, etoricoxib is well absorbed, is metabolized extensively via oxidation (6'-methyl oxidation >1'-N-oxidation), and the metabolites are excreted largely in the urine.
Choosing the Right Nonsteroidal Anti-Inflammatory Drug for the Right Patient
TLDR
The major differences between NSAIDs are their therapeutic half-lives and safety profiles, and individual patient-specific and NSAID-specific pharmacokinetic principles should be considered.
The Effects of Modifying In Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity
TLDR
Etoricoxib had no effect on hepatic CYP3A activity, as assessed by the erythromycin breath test, and coadministration of etoricxib with daily doses of rifampin had a potentially clinically important effect on etoricoxIB pharmacokinetics.
Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment
TLDR
The effect of hepatic insufficiency on the pharmacokinetics of etoricoxib was investigated following administration of single and multiple oral doses to mild and moderate hepatic Insufficiency patients, and Binding of etricoxib to plasma proteins was also found to be unaffected by hepatic disease.
...
1
2
3
4
5
...